Yetunde Sokunbi
Family Medicine · Houston, TXNPI 1952664823
Payments from drug & device makers
Across 78 payments — averaging $13.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$217
- GSK$128
- AstraZeneca$92
- AbbVie$75
- Radius Health, Inc.$67
- Amgen$65
- plus $382 from 15 others
What the payments were for
- Food & beverage$1,026100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $217 |
| GSK | 13 | $128 |
| AstraZeneca | 5 | $92 |
| AbbVie(2 entities) | 4 | $75 |
| Radius Health, Inc. | 3 | $67 |
| Amgen | 4 | $65 |
| Amneal Pharmaceuticals LLC | 4 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $50 |
| Astellas Pharma US Inc | 3 | $46 |
| Bayer | 2 | $41 |
| Lilly USA, LLC | 2 | $32 |
| Shire North American Group Inc | 2 | $31 |
| Vertiflex, Inc. | 1 | $22 |
| Pfizer | 1 | $17 |
| Cranial Technologies, Inc | 1 | $14 |
| Kaleo, Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Mannkind Corporation | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Circassia Inc. | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $10 |
How this compares
$1,026 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 123 | $37,121 |
| TrulicityDulaglutide | 19 | $26,794 |
| OzempicSemaglutide | 25 | $24,865 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 105 | $21,926 |
| JardianceEmpagliflozin | 21 | $17,719 |
| JanuviaSitagliptin Phosphate | 12 | $17,139 |
| EliquisApixaban | 22 | $16,804 |
| FarxigaDapagliflozin Propanediol | 13 | $12,610 |
| Atorvastatin Calcium | 319 | $8,852 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 57 | $3,707 |
| Losartan Potassium | 181 | $3,613 |
| Rosuvastatin Calcium | 66 | $2,967 |
| Metoprolol Succinate | 87 | $2,248 |
| Ezetimibe | 12 | $2,212 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 22 | $2,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerAbrysvo, Eliquis | $17 | $53,925145 claims |
| Lilly USA, LLCTrulicity | $32 | $26,79419 claims |
| Novo NordiskOzempic | $217 | $24,86525 claims |
| GSKShingrix | $128 | $21,926105 claims |
| AstraZenecaFarxiga | $92 | $12,61013 claims |
| AbbVieSynthroid | $75 | $58613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.